Pierre Fabre, Merck KGaA team up for MEK-BRAF-Erbitux cancer combo trial

Pierre Fabre, Toulouse

Pierre Fabre, Merck KGaA and Array BioPharma ($ARRY) have teamed up to trial a triple combination therapy in a hard-to-treat subpopulation of colorectal cancer patients. The Phase III trial will test the BRAF and MEK inhibitors Pierre Fabre licensed from Array last year in combination with Merck KGaA’s Erbitux.

By combining binimetinib and encorafenib, the aforementioned late-phase MEK and BRAF inhibitors, with Merck KGaA’s established colorectal cancer drug Erbitux, Array and its partner Pierre Fabre think they have a shot at treating patients with BRAF-mutant forms of the disease. The trial will randomize 615 patients to receive either the binimetinib-encorafenib-Erbitux triple combination, just the latter two drugs or a control mix of Merck KGaA’s drug and irinotecan-based therapy.

The primary endpoint is the overall survival associated with the triple therapy in comparison to the control arm. Investigators will also compare the triple combination to the encorafenib-Erbitux mix, and the latter to the control arm, as part of a suite of secondary efficacy measures. Progression-free survival, objective response rate, duration of response, safety and quality-of-life measures will be assessed by the secondary endpoints.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Castres, France-based Pierre Fabre will cover 40% of the cost of the clinical trial, the same share of R&D spend it committed to when it licensed the European rights to binimetinib and encorafenib from Array in a $455 million (€400 million) deal last year. The outcome of the trial will go some way to determining the success, or otherwise, of the deal, as well as what proportion it will pay of the $425 million in milestones attached to the agreement.

The Array deal was the headline event in a busy year for Pierre Fabre’s cancer business development team, which entered into 7 agreements in 2015. This flurry of activity followed a decision late in 2014 to lay off 272 researchers and focus R&D activities on oncology, neuroscience and dermatology, actions that upped the importance of both cancer and external alliances to the company.

- read the release
- and EP Vantage’s take

Related Articles:
Pierre Fabre starts open-ended collaborative translational R&D fund
Moving on from Novartis, Array inks a $455M oncology deal with Pierre Fabre
Pierre Fabre dives into hot PD-1 field with a biotech tie-up

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.